TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Percentage of Responders
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Somatosensory evoked potential amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Identification of genetic alterations and protein changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Functional beta cell mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percentage of Participants Achieving Erythroid Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Presence of alpha-synuclein aggregates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Mental Health-related Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Daily blood glucose mean concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Worst Daily Pain After Surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Counter movement jump
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IVAR test system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of Temozolomide (TMZ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median Amount of Time Participant Survives Without New Brain Lesions
Endpoint domain: Mortality/survival
Primary endpoint: Standard deviation of all R-R intervals (SDNN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lower Extremity Measure (LEM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of BK Polyomavirus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Engagement with mental health provider
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Corticomotor excitability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Occurrence of first total appropriate therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of serum bilirubin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morning serum cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Standard safety laboratory tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early and sensitive diagnosis of Mucolipidosis disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence and intensity of local and systemic adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Self efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Brachial Artery Diameter Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of symptomatic hyponatremia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Cigarette Craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % of patients with a post-operative infection
Endpoint domain: Adverse events/effects
Primary endpoint: Percent of Practices that have Mechanisms in Place to Identify Primary Caregivers
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percent of Practices that have Mechanisms in Place to Provide Psychosocial and/or Needs Assessments for Caregivers
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percent of Practices that have Availability of and Funding Models for Supportive Care Services
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Total Adverse Events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Referral Rates to Local Hospitals
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Neonatal Deaths
Endpoint domain: Mortality/survival
Primary endpoint: Failure at the spontaneous breathing trial
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of heavy menstrual bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in FEV1%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Total Number of Gadolinium-Enhancing T1 Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline in serum creatinine level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Patient and physician-assessed symptom scales
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of patients converted to inpatient or re-admitted within 24h
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Female Sexual Function Index (FSFI) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in MDS-UPDRS III Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Change in HbA1c %
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Engagement in risky sexual behavior
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Presence of primary and/or metastatic renal cell carcinoma by IMP3 autoantibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Presence of primary and/or metastatic renal cell carcinoma by miRNA/snRNA signature
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Response (CR/PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Frequency of Dose-limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of vomit and dizziness after the procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Serum Ferritin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Transferrin Saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in brain connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Blood exposure levels of GW685698X
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Steps Completed in Transplant Process
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Summed Pain Intensity Difference (SPID-8)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Easy Breathing Surveys Distributed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: number of new genetic variants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention rate of restoration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: amyloid accumulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Episodes of acute respiratory infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Episodes of diarrheal disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of Treatment Emergent Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in Karolinska Sleepiness Scale
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Reduced incidence of adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Reduced incidence of serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Composite of all-cause mortality or stroke
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients discharged the next day after elective transfemoral TAVR
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Hamilton Depression Rating Scale 17
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: day 100 treatment-related mortality (TRM)
Endpoint domain: Mortality/survival
Primary endpoint: Change in Serum Inorganic Phosphorus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Smoking cessation (point prevalence)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of recovery from anaesthesia
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: duration of supplemental oxygen requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Clinical and Endoscopic Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depressive Relapse or MDD
Endpoint domain: Adverse events/effects
Primary endpoint: Episodic Memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Body Composition (BODPOD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Insulin Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in Clinical Global Impression-Severity (CGI-S) scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of adverse events complication rate
Endpoint domain: Adverse events/effects
Primary endpoint: Ophthalmologic exam - Vision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ophthalmologic exam - IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of nystagmus and disequilibrium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 24 hour glycemia measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Insulin resistance evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Total Weight Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Marginal bone stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Frequency of race-related splice variants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Improvement in wrinkles appearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in the absolute number of CMV-induced adaptive NK cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Tic frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in benzodiazepine and Non-benzodiazepine hypnotics consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Serrated polyp detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Biochemically-validated tobacco abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Continuous Abstinence From Smoking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Chest Infections
Endpoint domain: Adverse events/effects
Primary endpoint: Changes of length of the Stop Signal Reaction Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes of the length of Reaction Times and Movement Times
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Photosensitivity of the skin to UVA and UVB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in range of motion of the proximal interphalangeal joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Acute and Late rectal morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Acute and Late urinary morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: reductive scores of Montgomery-Asberg Depression Rating Scale (MADRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Multifidus muscle fat infiltration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Development of phobias
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pharmacokinetics of Ticagrelor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression of white matter hyperintensities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in nasal congestion and headache scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of Colorectal cancer screening
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: change in taste sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: alteration of transcriptomic profile of human tongue tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in motoneuron excitability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in spinal excitability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in flexor reflex/spasms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in functional movement performance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Circadian intraocular pressure patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heterotopic bone volume change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean changes from baseline in MMSE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Distributions of CIBIC-plus (ADCS CGIC)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Best clinical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of bleomycin in treating non-Hodgkin's lymphoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Maximum Tolerated Dose (MID)
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of COVID-19
Endpoint domain: Mortality/survival
Primary endpoint: Standardized Mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: Treatment Failure (PCR adjusted)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety profiles including significant changes in relevant laboratory values
Endpoint domain: Adverse events/effects
Primary endpoint: Active Range of Motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Lesions Requiring Adjunctive Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Numerical Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: number of rehospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Difference in weekly steps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in N-Back Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: blastulation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Whole blood NAD+ levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in level of pain interference with activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: AUC 0-4h of MMTT Stimulated C-peptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of CT scans or CT fluoroscopic images
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Visual Vertigo Analogue Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Vertigo Handicap Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Dizziness Handicap Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants With Adverse Drug Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Response to diabetes therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of diabetes progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in pre-dose morning FEV1 (L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: visual analog scale (VAS) scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Limb Volume (ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Limb Volume (% Change)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Skin Tone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Reported Outcomes - MYMOP
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: GLP-2 plasma levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Myocardial Energetic Efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Viable Myocardial Energetic Efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Severity of Depression Using Hamilton Depression Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Severity of Depression Using the Patient Health Questionnaire-9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Meeting Criteria for Major Depressive Disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Anti-HBs Seroprotected Participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-HBs GMT (Geometric Mean Titer)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Major Colorectal Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Tip Placement efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in aerobic fitness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence and compliance to the exercise training intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: pain scales
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRI T2 BOD at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute Mean Change in Iris Pigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biochemically validated smoking abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluticasone propionate AUCtau
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Salmeterol Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tap frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean hand movement time between taps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Actual distance between taps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pain free/maximum grip strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of pulmonary hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean change in best-corrected visual acuity (BCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Fusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Aspirin Resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: iHOT-33 score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Trust score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Success treatment proportion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Seroprotection Against Diphtheria and Tetanus Antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Booster Response to Diphtheria and Tetanus Antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes